NCT06105827View on ClinicalTrials.gov

Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy

PHASE4CompletedINTERVENTIONAL

Enrollment

251

Participants

Timeline

Start Date

October 2, 2016

Primary Completion Date

April 25, 2019

Study Completion Date

April 25, 2019

Conditions

Ureteral Calculi

Interventions

DRUG

Control group

Give antibiotics or diclofenac sodium suppository as needed.

DRUG

Ningmitai capsule

Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.

DRUG

Combined group (Ningmitai plus tamsulosin)

Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.

All Listed Sponsors

lead

Xintian Pharmaceutical

INDUSTRY

NCT06105827 - Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy | Biotech Hunter | Biotech Hunter